Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
There are no documented adverse events for BPC-157, and its lethal dose is extremely high.
The finding
What the evidence shows
The lethal dose part has real support, since animal safety work has not been able to establish a minimum toxic dose or a lethal dose for BPC-157. But no documented adverse events goes further than the record allows. In its review of BPC-157 for pharmacy compounding, the FDA said the peptide may pose an immunogenicity risk and impurity problems, and that the agency lacks sufficient information to know whether the drug would cause harm when given to humans. Published human use adds up to roughly 30 people across three small studies, so the quiet safety record mostly reflects how little it has been studied.
Read the supporting source · www.fda.gov ↗Quick answer & review status
Quick answer
Is it true that there are no documented adverse events for BPC-157, and its lethal dose is extremely high?
Partly. The claim stretches what the evidence shows. The lethal dose part has real support, since animal safety work has not been able to establish a minimum toxic dose or a lethal dose for BPC-157. But no documented adverse events goes further than the record allows. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 1:58:07. The supporting source is fda.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.